Abstract
Genetic lesions and other regulatory events lead to silencing of the 13q14 locus in a majority of chronic lymphocytic leukemia (CLL) patients. This locus encodes a pair of critical proapoptotic microRNAs, miR-15a/16-1. Decreased levels of miR-15a/16-1 are critical for the increased survival exhibited by CLL cells. Similarly, in a de novo murine model of CLL, the NZB strain, germline-encoded regulation of the syntenic region resulted in decreased miR-15a/16-1. In this paper, we have identified additional molecular mechanisms regulating miR-15a/16-1 levels and have shown that the transcription factor BSAP (B-cell-specific activator protein) directly interacts with Dleu2, the host gene containing the miR-15a/16-1 loci, and by negative regulation of the Dleu2 promoter, results in repression of miR-15a/16-1 expression. CLL patient B-cell expression levels of BSAP were increased compared with control sources of B cells. With the use of small interfering RNA-mediated repression, the levels of BSAP were decreased in vitro in the NZB-derived malignant B-1 cell line, LNC, and in ex vivo CLL patient peripheral blood mononuclear cells (PBMCs). BSAP knockdown led to an increase in the expression of miR-15a/16-1 and an increase in apoptosis, and a cell cycle arrest in both the cell line and patient PBMCs. Moreover, using Dleu2 promoter analysis by chromatin immunoprecipitation assay, we have shown that BSAP directly interacts with the Dleu2 promoter. Derepression of the Dleu2 promoter via inhibition of histone deacetylation combined with BSAP knockdown increased miR-15a/16-1 expression, and also increased malignant B-cell death. In summary, therapy targeting enhanced host gene Dleu2 transcription may augment CLL therapy.
Similar content being viewed by others
Introduction
Chronic lymphocytic leukemia (CLL) is an age-associated B-cell malignancy characterized by the accumulation of hyperdiploid B-1 cells in the bone marrow, spleen and blood.1 It is the most common lymphoid malignancy in the western hemisphere. Since its first documented diagnosis more than 150 years ago, the etiology of CLL is largely unknown and it remains incurable with current therapy.2 FCR therapy—combination of Fludarabine, Cyclophosphamide and Rituximab—is the new gold standard for CLL therapy.3 Although the response rate to therapy is higher as compared with other cancers, almost all patients relapse because of persistence of minimal residual disease.4, 5 Hence, novel treatment strategies need to be developed. Modulating microRNA expression is one such promising but underexplored therapeutic area.6 We have previously shown that miR-15a/16-1 upregulation is one such promising therapeutic strategy.7
The 13q14 (region that encodes miR-15a/16-1 in humans) deletion is the most common chromosomal abnormality in CLL, occurring in 50–60% of patients.8 It is believed to encode critical tumor suppressor genes, as it is frequently deleted or silenced in various other malignancies like prostate cancer, mantle cell lymphoma and multiple myeloma.9, 10, 11 Detailed cytogenetic analysis has revealed the presence of a 130-kb minimal deleted region centromeric to the marker D13S272 that contains several candidate tumor suppressor genes like Dleu1, Dleu2, Dleu5 and Dleu7.12, 13 However, currently only Dleu2 (host gene of miR-15a/16-1) and Dleu7 have been demonstrated to have tumor-suppressive functions in CLL.14, 15
MicroRNAs are often located in intronic regions within host genes, which can be both coding and non-coding host genes.16 Mir-15a/16-1 is encoded within an intronic region of the non-coding Dleu2 gene in both human and mouse, and is transcribed off the Dleu2 promoter. A point mutation (in several CLL patients and NZB mice—de novo mouse model of CLL) and a point deletion (in NZB mice) in the 3′-flanking region of mir-16-1 was discovered and was associated with 50% reduction in the expression of mature miR-15a/16-1 in patients as well as in NZB mice and LNC cell line (NZB-derived mouse B-CLL line).17, 18, 19 Correcting the reduced miR-15a/16-1 level gives rise to growth inhibitory effect.20 To develop strategies to modulate miR-15a/16-1 levels, it is imperative to understand the molecular mechanisms that control its expression.
BSAP (B-cell-specific activator protein), encoded by the Pax5 gene, acts as a transcription factor and contains a DNA-binding domain, and recently it has been shown that BSAP negatively regulates Dleu2, the host gene of mir-15a/16-1 in mouse lymphoma cells.21 BSAP is expressed at the pro-B-cell stage and is maintained until the plasma cell stage is reached.22 BSAP can function either as an oncogene or a tumor suppressor depending on the cell type.23 BSAP can result in increased or decreased gene expression and this can be regulated by additional proteins that BSAP is capable of interacting with via its protein-binding domain. BSAP overexpression generally confers proliferative phenotype in lymphoid malignancies, especially B-ALL.24, 25 In light of this background, we explored the BSAP-Dleu2 regulation in mouse and human CLL cells. It has become increasingly clear that combination therapies are much more effective at fighting cancer (reviewed in Humphrey et al.26). Hence, we also report herein the combined effect of BSAP knockdown and histone deacetylase (HDAC) inhibition (HDAC activity is increased in CLL) on miR-15a/16-1 levels and malignant cell death.
Results
BSAP levels are increased and inversely correlate with miR-15a/16 levels in B-1 malignant cells from CLL patient PBMCs
PBMCs from untreated CLL or age-matched normal controls were stained for surface expression of CD19 and CD5 and intracellular levels of BSAP. Cells were gated on CD19+ (B-cell gate) and the mean fluorescence intensity (MFI) of BSAP determined (Figure 1a). The BSAP levels in a non-B-cell source, patient T cells (CD3+, CD19−), is shown for comparison. The CLL B cells demonstrated increased expression of BSAP when compared with non-CLL sources. However, all sources of B cells had increased expression of BSAP relative to their T-cell population. In addition, the CLL B cells were sorted into two different B-1 populations, CD19+CD5+ BSAPhi and CD19+CD5+BSAPlo (Figure 1b). RNA was obtained from the sorted populations and analyzed by polymerase chain reaction (PCR) for the expression of miR-15a. The B-1 cells with high BSAP had reduced levels of miR-15a relative to the expression in B-1 cells with low expression of BSAP (Figure 1b). Similarly, as miR-15a/16-1 targets Bcl-2, the expression of Bcl-2 was low in the BSAP low-expressing CLL cells, suggesting that the resultant high levels of miR-15a/16-1 permit these cells to readily undergo apoptosis. Indeed, the BSAP low cells are the minor population of B-1 cells in the CLL patient. Hence, we hypothesized that by knocking down BSAP via small interfering (si)BSAP, miR15a/16-1 levels will be increased and their target Bcl-2 decreased, which would lead to the induction of apoptosis.
Negative regulation of miR-15a/16-1 by BSAP can be exploited for CLL therapy
CLL is a very heterogeneous disease, but downregulation of miR-15a/16-1 remains the single most commonly occurring pathological event in >70% of CLL patients.27 Hence, we hypothesized that by attenuating the BSAP-mediated negative regulation of the promoter of the host gene for miR-15a/16-1, we can increase miR-15a/16-1 levels in ex vivo-treated patient PBMCs. Total PBMCs isolated from patient blood were used for the BSAP knockdown studies instead of purified B-1 cells, as >90% of the PBMCs were malignant CD19+CD5+ B-1 cells (Figure 2a). BSAP expression was knocked down by about 25% using siRNA-BSAP as compared with the Neg. CTRL siRNA (Figure 2d). The reduced expression of BSAP translated into a significant increase in the expression of miR-15a/16-1 (Figure 2b). Different patients exhibited different kinetics of BSAP knockdown and hence the peak reduction in BSAP is shown. BSAP positively regulates CD19 expression and post siRNA-BSAP treatment, CD19 expression was reduced, further validating the success of the BSAP knockdown (Figure 2e). As the CLL patient PBMCs are not actively cycling, increase in the percentage of apoptotic cells was used as a readout for biologically significant increase in miR-15a/16-1 expression, instead of cell cycle analysis. The percentage of Annexin V+ cells (apoptotic cells) was significantly higher in the siRNA-BSAP-treated group as compared with the Neg. CTRL-treated group (Figure 1f), indicating that reduction in BSAP induced by siRNA-BSAP increased both the level of miR-15a/16-1 and the amount of apoptosis.
BSAP regulates miR-15a/16-1 expression at the level of host gene transcription
Many microRNAs are encoded within the introns of other bigger coding or non-coding genes, with or without their own promoters. In the latter case, the expression of the encoded miR would depend on the promoter status of the host gene. To confirm that BSAP regulates Dleu2 transcription (host gene for mir-15a/16-1), the Dleu2 mRNA level was measured in the CLL patient PBMCs following siRNA-BSAP. A significant increase was observed in the expression of Dleu2 following BSAP knockdown (Figure 2b). The increase in Dleu2 was found to be positively correlated to the level of miR-15a/16-1 (Figure 2c). Hence, we conclude that BSAP inhibits mir-15a/16-1 expression by inhibiting the transcription of its host gene, Dleu2. This was further verified by fluorescence in situ hybridization (FISH) analysis at a single-cell level to quantitate simultaneously the amount of Pax5 mRNA (which encodes the BSAP protein) and the amount of Dleu2 mRNA. In non-CLL B cells, the amount of Pax5 (BSAP) was decreased relative to the CLL B cells (Figure 3). In addition, the amount of Pax5 expression was inversely related to the amount of Dleu2 on a single-cell level (Figure 3), with CLL B cells having low levels of miR-15a/16 expression and high levels of BSAP and non-CLL B cells expressing lower levels of BSAP but higher levels of miR15a.
BSAP interacts with Dleu2 promoter
It is currently unknown whether BSAP regulates Dleu2 promoter directly or indirectly. Promoter analysis using CONSITE failed to show any canonical BSAP binding sites in the human Dleu2 promoter. However, we cannot rule out the possibility that BSAP might be present in a complex with some of its binding partners at the Dleu2 promoter. Binding sites for some of the proteins that BSAP has been known to interact with were found in the human Dleu2 promoter (c-Myb, AML1 and E2F). We performed a chromatin immunoprecipitation (ChIP) assay on Daudi cells to assess BSAP-Dleu2 promoter interactions. Daudi is a B lineage cell line (Burkitt’s lymphoma) and has BSAP expression.28 Similar to the positive control of CD19 promoter, the Dleu2 promoter was enriched in the BSAP pulldown. No enrichment of the negative control Kras promoter was observed (Figures 4a and b). The ChIP assay was performed using four CLL PBMC samples in four independent pulldown experiments (Figure 4c). The Dleu2 promoter region was also enriched in the CLL samples and was similar to a known promoter, which encodes a BSAP binding site, the CD19 promoter. In contrast, the Kras promoter, which does not encode a BSAP binding site, was not pulled down in CLL samples (Figure 4c). These data suggest that a BSAP binding site is present at the Dleu2 promoter in human B cells. However, a canonical BSAP binding site was found at +676 position in the mouse Dleu2 gene. A ChIP assay was performed on murine B cells, the LNC cells, to assess BSAP-Dleu2 promoter interactions. As we knew the position of the putative BSAP binding site in mouse Dleu2, we were able to design a ChIP assay having an internal control in addition to the glyceraldehyde 3-phosphate dehydrogenase control as shown in Figure 4d. Indeed, the Dleu2 promoter fragments were enriched in the BSAP pulldown and the amount of enrichment was inversely proportional to the distance from the BSAP binding site (Figure 4e). The upstream sequences (U) were not as enriched by the BSAP pulldown as were the downstream sequences (D), which contained the BSAP binding site. The presence of the Dleu2 U region in the BSAP pulldown may be because of DNA fragments, which contain both the D and U region. The human data indicating BSAP interaction with the Dleu2 promoter were validated in the mouse system, which has a canonical BSAP binding site in its promoter.
BSAP knockdown leads to cell cycle arrest and apoptosis in NZB
We and others have previously shown that miR-15a/16-1 expression is reduced by almost 50% in CLL (in both patients and NZB mice).20 Using microarray-based expression analysis, negative correlation was shown between BSAP and Dleu2 (host gene of miR-15a/16-1) levels in Myc5 cells.21 Myc5 is a B-lymphoma cell line derived by transducing p53-null bone marrow cells with c-Myc retrovirus. These cells can oscillate between B-cell and macrophage lineages based on the culture conditions and BSAP levels in vitro.29 On the contrary, LNC is a natural malignant B-1 cell line derived from the spontaneously occurring murine model of human CLL and has constitutively very high levels of BSAP expression and low levels of miR-15a/16-1 expression (Supplementary Figure S1). In light of the above disparities in the two systems, we wanted to confirm whether BSAP could negatively regulate miR-15a/16-1 levels in our system.
The NZB-derived CLL cell line LNC was transfected with either 3 μg non-targeting negative control siRNA (Neg.CTRL) or with 3 μg siRNA BSAP (siRNA-BSAP), using Amaxa Nucleofection (Lonza, Walkersville, MD, USA), to transiently knockdown BSAP. The expression of BSAP was reduced as early as 12 h post-transfection and the suppression began to diminish after 48 h. Flow cytometric analysis via histogram overlays of BSAP levels on a per cell basis showed a decrease in BSAP in siRNA-treated cells compared with Neg.CTRL-treated cells as early as 12 h post-transfection (Figure 5a). The average BSAP MFI at different time-points post-transfection is shown in Figure 5b and was found to be lowest at 24 h post siRNA-BSAP treatment when compared with the Neg.CTRL at that time-point (P<0.05). BSAP protein was reduced by 53% at 24 h as compared with the Neg.CTRL. The miR-15a levels were measured in cells with successful knockdown of BSAP to determine the potential causal relationship between BSAP and miR-15a/16-1 expression in our system. The miR-15a level was measured using TaqMan MicroRNA Assays (Applied Biosystems, Carlsbad, CA, USA) and an approximately twofold increase in miR-15a levels was observed in the siRNA-BSAP-treated cells at 24 h (P<0.05) (Figure 5c). Interestingly, the increase in miR-15a expression corresponded with the peak reduction in BSAP, suggesting a strong influence of BSAP on the expression of the microRNA. LNC cells mimic aggressive CLL and are very rapidly dividing. We and others have shown that an increase in miR-15a/16-1 leads to cell cycle arrest and reduced proliferation.30, 31, 32 Initially, we have shown that reducing BSAP levels results in an increase in miR-15a/16-1 expression. To test the biological significance of this, the increased miR-15a/16-1 should result in decreased downstream targets like cyclin D, leading to cell cycle arrest. As compared with the Neg.CTRL-treated cells, which have baseline level of BSAP and miR-15a/16-1, the siRNA-BSAP-treated cells exhibited a significant increase in the percentage of cells in the G1 phase and a reduction in the percentage of cells in the S phase (Figures 5d and e, P<0.05). Moreover, we also observed a decrease in the expression of cyclin D1 in the siRNA-BSAP-treated cells as compared with the Neg.CTRL-treated cells (Figure 5f), indicating that the cell cycle arrest is a direct consequence of increased miR-15a/16-1, as it has been shown to be an important regulator of cyclin D1.
Combination treatment with HDAC inhibitor
Next, we wanted to assess whether the antiproliferative effect of BSAP knockdown can be enhanced by using an HDAC inhibitor. LNC cells were treated with siRNA-BSAP and the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) (clinically known as vorinostat). Dose–response curves were calculated for SAHA (data not shown) and a suboptimal dose of 0.8 μM was selected for the combination treatment. An additive effect was observed on the increase in the %G1 (Figure 6a) and decrease in %S (Figure 6b) as compared with the untreated cells. However, a synergistic effect was observed in the percentage of cells undergoing apoptosis when treated with the siRNA BSAP and SAHA together (Figure 6c). In addition, we observed a significant increase in miR-15a/16-1 expression following treatment (Figure 6d). To confirm that the observed cell cycle and apoptosis effects are mediated by increased miR-15a/16-1, LNC cells were treated with SAHA+siRNA BSAP+antagomiR to miR-15a and miR-16-1. The antagomiR lead to a stable reduction in miR-15a/16-1 up to 48 h post-transfection (Figure 6e). This gave rise to a partial rescue from increased malignant cell death (Figure 6f). In conclusion, these findings indicate that the combination of HDAC inhibition and BSAP knockdown leads to a significantly higher increase in malignant cell death in part by increasing the level of miR-15a/16-1.
Discussion
In this study, we found that in CLL patients, B cells constitutively express higher levels of BSAP than do control sources of B cells. However, within a CLL malignant clone, a minority of the B-1 cells had relatively low levels of BSAP. Analysis of the two types of B-1 cells demonstrated that increased expression of the microRNA miR-15a/16-1 was found in the patient B-1 subpopulation with the higher expression of BSAP (minor population). To further dissect the role of BSAP in the regulation of the levels of miR-15a/16-1, addition of siRNA pools with antisense regions to the Pax5 gene (which encodes BSAP) resulted in an increase in miR-15a/16-1 levels. Taken together, these studies indicate that BSAP is a negative regulator of miR-15a/16-1. The BSAP-mediated regulation of miR-15a/16-1 levels is occurring at the level of the host gene transcription as seen by the significant positive correlation between Dleu2 and miR-15a/16-1 levels that is dependent on the BSAP levels and independent of downstream mutations in that loci. This was also observed at the level of single-cell RNA FISH analysis. We have also shown that BSAP interacts with the Dleu2 promoter (direct interaction in mice and indirect interaction in humans). This finding is very interesting given that the human Dleu2 promoter lacks a canonical BSAP binding site. We speculate that BSAP interacts with another protein that binds to the Dleu2 promoter directly and this complex is responsible for the repression of the Dleu2 promoter. This report concentrated on Dleu2 promoter repression and other studies have also indicated that the Dleu2 promoter regulates miR15a/16 levels.33 However, a potential promoter region located near the mir15a/16-1 loci within Dleu2, which has myb binding sites, has been reported and myb interacts with BSAP.34 Further studies need to be performed to identify binding partners of BSAP and additional promoter regulation of miR15a/16.
Earlier studies focused mainly on the role of BSAP in the B-cell lineage development program.35 This study highlights the role of BSAP in cancer cell survival via its regulation of an important pro-apoptotic microRNA cluster, mir-15a/16-1. BSAP appears to act as an oncogene in CLL and has an important role in downregulating mir-15a/16-1, a known tumor suppressor in CLL. Other groups have also demonstrated the role of BSAP in regulating apoptosis.36 Previously, we demonstrated that inhibition of BSAP leads to decreased proliferation and apoptosis in malignant B-1 cells from the NZB murine model of CLL.37, 38, 39 In this study, we have shown that knocking down BSAP leads to malignant cell death not only in our murine CLL cell line but also in ex vivo patient PBMCs via upregulation of miR15a/16 levels. We propose that targeting BSAP using siRNA or small-molecule inhibitors could serve as a novel therapeutic strategy for CLL. The role of BSAP in tumorigenesis is highly cell type specific, in that it can act both as an oncogene (non-Hodgkin’s lymphoma, neuroblastoma) or as tumor suppressor (multiple myeloma).40, 41, 42, 43 Targeting BSAP has already been shown to have therapeutic effects in other types of cancers like small-cell lung cancer.44 BSAP has been shown to be a positive regulator of CD19 and indirectly to control c-myc levels via regulation of CD19.45 In these studies, BSAP binding to the promoter region of CD19 in the ChIP analysis was verified and the additional binding to the promoter of Dleu2 (and miR15a/16-1) determined. The elevated levels of BSAP found in CLL malignant B-cell clones may have multiple effects in addition to negative regulation of miR15a/16 via repression of Dleu2 including elevation of c-myc via upregulation of CD19.
Because the bicistronic miR-15a/16-1 is a tumor suppressor microRNA,46 a wide variety of malignancies involve the repression of this microRNA cluster. There are different mechanisms by which this repression occurs. Several other studies have also found that the Dleu2 host gene promoter is repressed. Recently, c-Myc has been shown to repress the Dleu2 promoter via recruitment of HDAC3.47 HDAC activity is increased in a variety of cancers including CLL.48, 49, 50 HDACs have emerged as attractive targets in the treatment of both solid and hematological malignancies.51, 52, 53 Several groups have reported the efficacy of HDAC inhibitors in inducing CLL cell death in vitro and in clinical trials.54, 55 In addition to inducing direct cell death, HDAC inhibition also increases the immunogenicity of CLL cells, thereby facilitating antitumor immune response.56, 57 HDAC has also been shown to repress the Dleu2 promoter in CLL malignant B-1.58 Our results support these previous findings. We have shown that similar to BSAP-mediated Dleu2 repression, HDAC-mediated repression is also reversible and it opens up avenues for therapeutic intervention. Based on the data presented in this paper, we propose that BSAP and HDACs co-operate to bring about repression of the Dleu2 promoter in CLL. This study is critical because for the first time it simultaneously addresses the interaction between three important players (13q14 locus, BSAP and HDAC) involved in CLL pathogenesis. Out of the many genetic alterations found in CLL, the frequency of only 13q14 deletions is significantly elevated in MBL (monoclonal B-cell lymphocytosis), the precursor stage of CLL.59 In addition, epigenetic silencing of 13q14 has been found in CLL.60 This finding indicates that 13q14 silencing via its deletion or epigenetic modification is one of the first events leading to CD19+CD5+ B-cell expansion and understanding the regulation of this locus will be instrumental in delineating CLL etiology. A recent paper by Laurie et al.61 that analyzed clonal mosaicism in 50 000 subjects further underscores the importance of the 13q14 region in CLL.61 In this study, the authors discovered that 13q deletions were over-represented in normal subjects with age and its presence increased the chances of a future CLL diagnosis.
In summary, we have shown that in CLL, promoter regulation by a transcriptional repression via BSAP and HDAC co-coordinately repress Dleu2, the host gene of miR-15a/16-1, and targeting this loop leads to malignant cell death via increase in mature miR-15a/16-1 expression (Supplementary Figure S2).
Materials and methods
Patient samples and cell lines
A measure of 4–5 ml of blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes from untreated CLL patients after obtaining informed consent in accordance with UMDNJ (now Rutgers) and East Orange Veterans Administration New Jersey Health Care System human subjects Institutional Review Board. PBMCs were isolated from patient blood using Ficoll-Hypaque solution according to the manufacturer’s instructions (Stem Cell Technologies Inc., Vancouver, BC, Canada). Human Burkitt’s lymphoma cell line Daudi (ATCC No. CCL-213, Manassas, VA, USA) was used. In addition, the NZB- (murine model of human CLL) derived malignant B-1 cell line LNC was also used.62 Both cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 1% sodium pyruvate, 1% penicillin–streptomycin at 37 °C and 5% CO2.
siRNA nucleofection
A total of 2.5 × 106 PBMCs were nucleofected with 3 μg of ON-TARGETplus SMARTpool—siRNA targeting the Pax5 gene that encodes the BSAP protein (hereafter referred to as siRNA-BSAP) or ON-TARGETplus Non-targeting Pool siRNA (Neg.CTRL) as a control (Dharmacon, Lafayette, CO, USA) or nothing (mock) using Human B Cell Nucleofector Kit program with the AMAXA Instrument (Lonza, Switzerland). Similarly, 2.5 × 106 LNC cells were nucleofected with 3 μg of ON-TARGETplus SMARTpool—Mouse siRNA BSAP or ON-TARGETplus Non-targeting Pool siRNA as a control (Dharmacon) or nothing (mock) using Cell Line Nucleofector Kit T, program G-016 (AMAXA Instrument). % Reduction in BSAP protein was calculated as ((siRNA BSAP MFI−Neg.CTRL MFI)/Neg.CTRL MFI) × 100. The cells were harvested at different time points (24, 36, 48, 72 and 96 h) for further analysis. Wherever indicated, 1 μM each of antagomiRs to miR-15a and miR-16-1 (Dharmacon) were also nucleofected.
Surface and intracellular flow cytometry
Approximately 0.5 × 106 cells were stained with indicated surface antibodies for 25 min at 4 °C. Cells were then fixed and permeablized using BD Cytofix/Cytoperm kit (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer’s instructions and stained with the indicated intracellular antibodies for 30 min. Antibodies for surface markers were anti-human CD19-FITC (BD Biosciences), anti-human CD5-PE.Cy7 (BD Biosciences), and for intracellular markers were anti-human/mouse Pax5-PE (eBioscience, San Diego, CA, USA) and anti-mouse cyclin D1-AF647 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). The stained cells were acquired on BD LSR II (BD Biosciences) and analyzed using the FlowJo Software (TreeStar Inc., Ashland, OR, USA).
Sorting of B-1 cells and 100 cell PCR
CLL patient PBMCs were stained with CD19-FITC, CD5-PE.Cy7 and BSAP-PE antibodies. The CD19+ population in the lymphoid gate was further sorted into CD5+BSAPhi (B-1 BSAP hi) and CD5+BSAPlow (B-1 BSAP low) using the BD FACS Aria II cell sorter. Owing to the low number of cells obtained after sorting, we performed 100 cell PCR to measure the miR-15a/16-1 and Bcl-2 levels in the sorted subpopulations. Briefly, for the microRNA measurement, 100 cells in 4.84 μl 1 × phosphate-buffered saline were heat disrupted at 95 °C for 10 min to release RNA and immediately kept on ice. This extract was then used to prepare cDNA using the TaqMan microRNA RT Kit (Applied Biosystems), followed by real-time PCR. Bcl-2 levels were measured using the Power SYBR Green Cells-to-Ct Kit (Ambion Inc., Austin, TX, USA).
RNA isolation and quantitation
Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. MicroRNA-specific cDNA was prepared using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer’s instructions. The following pre-made TaqMan Assays (Applied Biosystems) were used for real-time quantitation—mmu-miR-15a (Assay ID 000389) and U6 (Assay ID 001973). Dleu2 transcripts were quantified from random hexamer-primed cDNA using TaqMan hsa-Dleu2 Assay (Applied Biosystems) (Assay ID Hs00863925 m1). MicroRNA and Dleu2 levels were normalized to U6 (mouse and human) and 18s rRNA (human), respectively.
Cell cycle and apoptosis assay
For cell cycle analysis, 0.5 × 106 were washed with 1 × phosphate-buffered saline and resuspended in 300 μl hypotonic propidium iodide solution, acquired on a BD Calibur IV cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using the ModFit LT Software (Verity Software House, Topsham, ME, USA). For apoptosis quantitation, cells were stained with Annexin V-PE (BD Bioscience) according to the manufacturer’s protocol, acquired on BD Calibur IV.
Chromatin immunoprecipitation
In total, 5 × 106 cells were crosslinked with 0.37% formaldehyde and sonicated to obtain 1-kb or 400-bp fragments using the S220 sonicator (Covaris Inc., Woburn, MA, USA). The ChIP-ready chromatin was pulled down with either goat anti-human Pax5 (Santa Cruz Biotechnology) or normal goat immunoglobulin G (IgG) (Santa Cruz Biotechnology). EpiTect One Day ChIP Kit (Qiagen) was used. The pulled down DNA was then used for real-time SYBR Green PCR of Dleu2 promoter using primers described in Bougel et al.63 CD19 promoter was used as a positive control and Kras promoter was used as the negative control. Similar protocol was followed for the mouse cell line. Dleu2 was primed at two separate sites (with and without the BSAP binding site as an internal control). CD19 was used as a positive control and glyceraldehyde 3-phosphate dehydrogenase was used as a negative control. Refer Supplementary materials (Supplementary Table S1) for mouse primer sequences.
HDAC inhibitor treatment
SAHA (clinically known as vorinostat57, 64) (Selleckchem, Houston, TX, USA) was dissolved in 100% ethanol to obtain a 10 mM stock. The final working concentration used was 0.8 μM.
RNA FISH
Dleu2 and Pax5 RNAs were imaged using single-molecule FISH probes as described previously.65 Briefly, a set of 35 probes was designed to hybridize to each target RNA and was synthesized with a 3′ amino modification from Biosearch Technologies (Novato, CA, USA). The individual probes for a given target were pooled in equimolar amounts and then coupled with succinimidyl ester of either TMR (for Dleu2) or Alexa 594 (for Pax5). The coupled fraction was purified using high-performance liquid chromatography and the concentration was determined using nanodrop. The coverslips were washed with 1 × phosphate-buffered saline, fixed in 4% formaldehyde, permeabilized with 70% ethanol and hybridized with the Dleu2 TMR and Pax5 Alexa 594 probes. Hybridization was carried out overnight at 37 °C. The coverslips were washed (with 10% formamide in 2 × SSC) to remove unbound probes and imaged using Zeiss wide field fluorescence microscope (Carl Zeiss, Thornwood, NY, USA). For each image, z-stacks were obtained and merged to get the final image. The image acquisition was carried out by Openlab software (Perkin-Elmer, Waltham, MA, USA) and numbers of mRNAs were counted using custom written alogrithms in MATLAB (MathWorks, Natick, MA, USA).66
Statistics
Data were analyzed with a paired Student’s t-test, unless otherwise specified. P<0.05 was considered significant.
References
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES . The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019–5032.
Piller G . Leukaemia—a brief historical review from ancient times to 1950. Br J Haematol 2001; 112: 282–292.
Montserrat E . Further progress in CLL therapy. Blood 2008; 112: 924–925.
Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80: 29–36.
Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980–988.
Kasinski AL, Slack FJ . Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849–864.
Kasar S, Salerno E, Yuan Y, Underbayev C, Vollenweider D, Laurindo MF et al. Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. Genes Immun 2012; 13: 109–119.
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.
Chang H, Li D, Zhuang L, Nie E, Bouman D, Stewart AK et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma 2004; 45: 965–969.
Chen L, Li J, Xu W, Qiu H, Zhu Y, Zhang Y et al. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. Exp Oncol 2007; 29: 116–120.
Flordal Thelander E, Ichimura K, Collins VP, Walsh SH, Barbany G, Hagberg A et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 2007; 31: 1219–1230.
Corcoran MM, Rasool O, Liu Y, Iyengar A, Grander D, Ibbotson RE et al. Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood 1998; 91: 1382–1390.
Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2098–2104.
Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28–40.
Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L et al. 13q14 Deletions in CLL involve cooperating tumor suppressors. Blood 2010; 115: 3916–3922.
Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A . Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14: 1902–1910.
Salerno E, Yuan Y, Scaglione BJ, Marti G, Jankovic A, Mazzella F et al. The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia. Cytometry B 2010; 78 (Suppl 1): S98–S109.
Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007; 109: 5079–5086.
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793–1801.
Salerno E, Scaglione BJ, Coffman FD, Brown BD, Baccarini A, Fernandes H et al. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol Cancer Ther 2009; 8: 2684–2692.
Chung EY, Dews M, Cozma D, Yu D, Wentzel EA, Chang TC et al. c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther 2008; 7: 1758–1764.
Medvedovic J, Ebert A, Tagoh H, Busslinger M . Pax5: a master regulator of B cell development and leukemogenesis. Adv Immunol 2011; 111: 179–206.
O'Brien P, Morin P Jr., Ouellette RJ, Robichaud GA . The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. Cancer Res 2011; 71: 7345–7350.
Firtina S, Sayitoglu M, Hatirnaz O, Erbilgin Y, Oztunc C, Cinar S et al. Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia. Leuk Res 2012; 36: 87–92.
Robichaud GA, Perreault JP, Ouellette RJ . Development of an isoform-specific gene suppression system: the study of the human Pax-5B transcriptional element. Nucleic Acids Res 2008; 36: 4609–4620.
Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst 2011; 103: 1222–1226.
Hanlon K, Rudin CE, Harries LW . Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). PLoS One 2009; 4: e7169.
Hamada T, Yonetani N, Ueda C, Maesako Y, Akasaka H, Akasaka T et al. Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14) (p13;q32) translocation in B-cell non-Hodgkin's lymphoma. Br J Haematol 1998; 102: 691–700.
Yu D, Allman D, Goldschmidt MH, Atchison ML, Monroe JG, Thomas-Tikhonenko A . Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 2003; 101: 1950–1955.
Scaglione BJ, Salerno E, Balan M, Coffman F, Landgraf P, Abbasi F et al. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br J Haematol 2007; 139: 645–657.
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944–13949.
Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105: 5166–5171.
Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43–50.
Zhao H, Kalota A, Jin S, Gewirtz AM . The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood 2009; 113: 505–516.
Cobaleda C, Schebesta A, Delogu A, Busslinger M . Pax5: the guardian of B cell identity and function. Nat Immunol 2007; 8: 463–470.
Crapoulet N, O’Brien P, Ouellette RJ, Robichaud GA . Coordinated expression of Pax-5 and FAK1 in metastasis. Anticancer Agents Med Chem 2011; 11: 643–649.
Zhang M, Raveche ES . Apoptosis induction in fludarabine resistant malignant B-1 cells by G2–M cell cycle arrest. Oncol Rep 1998; 5: 23–30.
Chong SY, Zhang M, Lin YC, Coffman F, Garcia Z, Ponzio N et al. The growth-regulatory role of B-cell-specific activator protein in NZB malignant B-1 cells. Cancer Immunol Immunother 2001; 50: 41–50.
Zhang M, Chong SY, Raveche ES . The role of B-cell-specific activator protein in the response of malignant B-1 cells to LPS. Exp Cell Res 2001; 264: 233–243.
Baumann Kubetzko FB, Di Paolo C, Maag C, Meier R, Schafer BW, Betts DR et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 2004; 25: 1839–1846.
Proulx M, Cayer MP, Drouin M, Laroche A, Jung D . Overexpression of PAX5 induces apoptosis in multiple myeloma cells. Int J Hematol 2010; 92: 451–462.
Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998; 92: 1308–1316.
Poppe B, De Paepe P, Michaux L, Dastugue N, Bastard C, Herens C et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 2005; 44: 218–223.
Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 2009; 89: 301–314.
Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A . CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest 2012; 122: 2257–2266.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524–15529.
Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012; 31: 3002–3008.
Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C et al. Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011; 81: 325–329.
Van Damme M, Crompot E, Meuleman N, Mineur P, Bron D, Lagneaux L et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 2012; 7: 1403–1412.
Barneda-Zahonero B, Parra M . Histone deacetylases and cancer. Mol Oncol 2012; 6: 579–589.
Khan O, La Thangue NB . HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85–94.
Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009; 4: 97–101.
Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res 2011; 17: 1582–1590.
Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010; 5: e10941.
El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NH et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 2010; 9: 1349–1360.
Dubovsky JA, Wang D, Powers JJ, Berchmans E, Smith MA, Wright KL et al. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res 2011; 35: 394–404.
Perez-Perarnau A, Coll-Mulet L, Rubio-Patino C, Iglesias-Serret D, Cosialls AM, Gonzalez-Girones DM et al. Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics 2011; 6: 1228–1235.
Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119: 1162–1172.
Lanasa MC, Allgood SD, Slager SL, Dave SS, Love C, Marti GE et al. Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. Leukemia 2011; 25: 1459–1466.
Mertens D, Philippen A, Ruppel M, Allegra D, Bhattacharya N, Tschuch C et al. Chronic lymphocytic leukemia and 13q14: miRs and more. Leuk Lymphoma 2009; 50: 502–505.
Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 2012; 44: 642–650.
Peng B, Sherr DH, Mahboudi F, Hardin J, Wu YH, Sharer L et al. A cultured malignant B-1 line serves as a model for Richter's syndrome. J Immunol 1994; 153: 1869–1880.
Bougel S, Renaud S, Braunschweig R, Loukinov D, Morse HC 3rd, Bosman FT et al. PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells. J Pathol 2010; 220: 87–96.
Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009; 2: 31.
Batish M, van den Bogaard P, Kramer FR, Tyagi S . Neuronal mRNAs travel singly into dendrites. Proc Natl Acad Sci USA 2012; 109: 4645–4650.
Batish M, Raj A, Tyagi S . Single molecule imaging of RNA in situ. Methods Mol Biol 2011; 714: 3–13.
Acknowledgements
This work was supported by NSF/FDA/SIR No. 1238375 and NIH R01CA12926 (ESR). Early Independence Award # 1DP5OD012160-01 (MB). We thank the UMDNJ-NJMS Flow Cytometry Core for their support.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Kasar, S., Underbayev, C., Yuan, Y. et al. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. Oncogene 33, 3307–3315 (2014). https://doi.org/10.1038/onc.2013.291
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.291
Keywords
This article is cited by
-
Circular RNAs in acute myeloid leukemia
Molecular Cancer (2021)
-
miR-151a-3p-rich small extracellular vesicles derived from gastric cancer accelerate liver metastasis via initiating a hepatic stemness-enhancing niche
Oncogene (2021)
-
Long noncoding RNA DLEU2 predicts a poor prognosis and enhances malignant properties in laryngeal squamous cell carcinoma through the miR-30c-5p/PIK3CD/Akt axis
Cell Death & Disease (2020)
-
Platelet RNA signatures for the detection of cancer
Cancer and Metastasis Reviews (2017)